Industry: Health care Region: Israel Transaction price: US$ 1 million Transaction method: equity investment
Project introduction:
A medical technology company in Israel was founded by continuous entrepreneurs in the field of medical devices and drug distribution, and has a multidisciplinary team composed of highly skilled personnel. The members of the expert team have decades of experience and focus on promoting the realization of oral biological products.
Oral biological preparation is the primary task of biotechnology companies, patients and health care providers, and it is often called the "holy grail" of drug delivery.
The company has developed a new generation of oral biological agent delivery platform, which will subvert the management of complex and biological drugs and change patient care. The company is currently developing an oral version of the world's best-selling injectable drugs:
Candidate products in preclinical stage are oral peptide (GLP1) and monoclonal antibody (anti-TNFa), involving more than $17 billion (expected to reach $50 billion by 2030) and more than $38 billion respectively.
The company has signed an evaluation agreement with a global top 40 biopharmaceutical company. At present, the potential of developing oral (once/twice a week) GLP1 capsules for treating diabetes and obesity in cooperation with biotechnology companies is being evaluated. The concept of this project is to load GLP1 molecules that have been approved by the US Food and Drug Administration into the company's innovative drug delivery system.
By 2030, the global market of GLP1 is expected to reach 50-60 billion US dollars, and the Asian market also has great potential.
Product advantages:
+Painless and noninvasive
+Quick, simple and highly specified treatment
+Effective provision of biotherapy drugs
+Bypass the biological barrier
Cooperation mode:
The company provides sales authorization and also looks for joint venture production partners. Welcome to discuss.